Positive results from Phase 2A clinical trial of TBA-7371, a new drug candidate for tuberculosis

BANGALORE, India, Nov. 29, 2023 /PRNewswire/ — Foundation for Neglected Disease Research (FNDR) is proud to announce that its partners, Bill & Melinda Gates Medical Research Institute and TB Alliance, have successfully completed the Phase 2A Early Bactericidal Activity clinical trial of TBA-7371, a novel DprE1 inhibitor for the treatment of tuberculosis. The results were presented at the 2023 Union World Conference on Lung Health in Paris. TBA-7371 was well tolerated and showed significant dose-dependent bactericidal activity with 14 days of treatment in patients with drug-susceptible pulmonary tuberculosis. TBA-7371 could have significant potential in the treatment of TB.

About the Foundation for Neglected Disease Research

Foundation for Neglected Disease Research (FNDR) is a not-for-profit biotech R&D organization dedicated to discovering and developing novel therapeutics, diagnostics, and devices for diseases with a high socio-economic impact. Since its inception in 2014, FNDR has generated a portfolio of therapeutics in tuberculosis, nontuberculous mycobacteria, malaria, dengue, leishmania, serious bacterial infections, fungal infections, COVID-19 and Influenza, spanning over early-stage discovery to late-stage clinical trials. FNDR’s R&D Centre, which includes state-of-the-art BSL2 and BSL3 laboratories for both in vitro and in vivo research, is located in Bengaluru, India.


Cision View original content:https://www.prnewswire.com/in/news-releases/positive-results-from-phase-2a-clinical-trial-of-tba-7371-a-new-drug-candidate-for-tuberculosis-302000187.html

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. India Shorts takes no editorial responsibility for the same.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Privacy & Cookies Policy